

Results of Fully Underwritten Entitlement Offer

Melbourne, Australia; 30 October 2026: [Cynata Therapeutics Limited](#) (ASX: “CYP”, “Cynata”, or the “Company”), advises the results of its fully underwritten pro-rata renounceable entitlement offer (**Entitlement Offer**). Under the Entitlement Offer, as announced on [8 October 2026](#), eligible shareholders with a registered address in Australia, New Zealand and Singapore (**Eligible Shareholders**) on the record date of 13 October 2026, were entitled to subscribe for three fully paid ordinary shares (**New Shares**) for every eight shares held, together with one free attaching option for every three New Shares issued (**Entitlement Options**), at an issue price of \$0.01 per New Share.

The Entitlement Offer was made pursuant to a replacement prospectus lodged with ASIC and ASX on [12 October 2026](#) (**Prospectus**) and closed at 5.00 pm AEDT on Tuesday, 27 October 2026 (**Closing Date**). Capitalised terms that are used but not defined in this announcement have the meanings given to them in the Prospectus.

Results of the Entitlement Offer

As at the Closing Date, the Company had received valid applications from Eligible Shareholders for 23,514,945 New Shares and 7,838,315 Entitlement Options, to raise approximately \$235,150 (before costs). This represents an overall take-up of approximately 25.8% of the New Shares offered under the Entitlement Offer.

The remaining 67,781,296 New Shares and approximately 22,593,765 Entitlement Options (**Shortfall Securities**) will be subscribed for by the underwriter, Caravel Securities Pty Ltd ACN 655 357 915 (**Underwriter**), in accordance with the Underwriting Agreement summarised in the Prospectus.

Following completion of the Entitlement Offer, the Company expects to raise a total of approximately \$912,962 (before costs).

Issue of New Shares, Entitlement Options and Underwriter Options

The New Shares, Entitlement Options and Underwriter Options are expected to be issued on Tuesday, 3 November 2026 and normal settlement trading of the New Shares is expected to commence on Wednesday, 4 November 2026.

New Shares issued under the Entitlement Offer will rank equally in all respects with the Company’s existing fully paid ordinary shares on issue. The Entitlement Options and Underwriter Options (which will not be quoted) will have an exercise price of \$0.02 and will be exercisable on or before 3 May 2029.

Further information on the Entitlement Offer is set out in the Prospectus (available at www.asx.com.au and cynata.com/announcements).

The Board thanks all shareholders who participated in the Entitlement Offer for their continued support of the Company.

-ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited’s (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Pty Ltd](#).